Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

249 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Lost Money in ChemoCentryx, Inc.?

May 12, 2021 at 14:12 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Gibbs Law Group Investigates Potential Securities Law Violations

ChemoCentryx, Inc. shares plummeted 45% on Tuesday May 4, 2021 after an FDA Briefing Document raised several serious concerns about ChemoCentryx’s leading drug candidate, avacopan. Gibbs Law Group is investigating a potential ChemoCentryx Class Action Lawsuit on behalf of investors who lost money in ChemoCentryx, Inc. (NASDAQ: CCXI).

To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.

On Tuesday, May 4, 2021, the FDA released a Briefing Document ahead of an Arthritis Advisory Committee meeting expressing concerns about ChemoCentryx’s new drug candidate, avacopan. Specifically, the FDA raised several serious concerns about the “complex” trial design, safety, and results of a late-stage drug study for avacopan, which is ChemoCentryx’s leading drug candidate for the treatment of anti-neutrophilic cytoplasmic autoantibody vasculitis.

Specifically, the FDA cited concerns about the “interpretability of the data to define a clinically meaningful benefit of avacopan.” The FDA report also noted that these concerns had previously been communicated to the company.

Following this news, ChemoCentryx’s stock price plunged 45% in intraday trading on May 4, 2021, causing significant harm to investors.

What Should ChemoCentryx Investors Do?

If you invested in ChemoCentryx, visit our website or contact our securities team directly at (888) 410-2925 to discuss how you may be able to recover your losses. Our investigation concerns whether ChemoCentryx, Inc. has violated federal securities laws by providing false or misleading statements to investors.

About Gibbs Law Group

Gibbs Law Group represents investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Cybersecurity/ Privacy Attorneys Under 40.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.